A specific nanobody prevents amyloidogenesis of D76N β2- microglobulin in vitro and modifies its tissue distribution in vivo

Sara Raimondi, Riccardo Porcari, P. Patrizia Mangione, Guglielmo Verona, Julien Marcoux, Sofia Giorgetti, Graham W. Taylor, Stephan Ellmerich, Maurizio Ballico, Stefano Zanini, Els Pardon, Raya Al-Shawi, J. Paul Simons, Alessandra Corazza, Federico Fogolari, Manuela Leri, Massimo Stefani, Monica Bucciantini, Julian D. Gillmore, Philip N. HawkinsMaurizia Valli, Monica Stoppini, Carol V. Robinson, Jan Steyaert, Gennaro Esposito, Vittorio Bellotti

Research output: Contribution to journalArticle

Abstract

Systemic amyloidosis is caused by misfolding and aggregation of globular proteins in vivo for which effective treatments are urgently needed. Inhibition of protein self-aggregation represents an attractive therapeutic strategy. Studies on the amyloidogenic variant of β2-microglobulin, D76N, causing hereditary systemic amyloidosis, have become particularly relevant since fibrils are formed in vitro in physiologically relevant conditions. Here we compare the potency of two previously described inhibitors of wild type β2-microglobulin fibrillogenesis, doxycycline and single domain antibodies (nanobodies). The β2-microglobulin -binding nanobody, Nb24, more potently inhibits D76N β2-microglobulin fibrillogenesis than doxycycline with complete abrogation of fibril formation. In β2-microglobulin knock out mice, the D76N β2-microglobulin/Nb24 pre-formed complex, is cleared from the circulation at the same rate as the uncomplexed protein; however, the analysis of tissue distribution reveals that the interaction with the antibody reduces the concentration of the variant protein in the heart but does not modify the tissue distribution of wild type β2-microglobulin. These findings strongly support the potential therapeutic use of this antibody in the treatment of systemic amyloidosis.

Original languageEnglish (US)
Article number46711
JournalScientific Reports
Volume7
DOIs
StatePublished - Jan 1 2017

Fingerprint

Single-Domain Antibodies
Tissue Distribution
Doxycycline
Amyloidosis
Proteins
Familial Amyloidosis
Antibodies
Therapeutic Uses
Knockout Mice
In Vitro Techniques

ASJC Scopus subject areas

  • General

Cite this

Raimondi, S., Porcari, R., Mangione, P. P., Verona, G., Marcoux, J., Giorgetti, S., ... Bellotti, V. (2017). A specific nanobody prevents amyloidogenesis of D76N β2- microglobulin in vitro and modifies its tissue distribution in vivo. Scientific Reports, 7, [46711]. https://doi.org/10.1038/srep46711

A specific nanobody prevents amyloidogenesis of D76N β2- microglobulin in vitro and modifies its tissue distribution in vivo. / Raimondi, Sara; Porcari, Riccardo; Mangione, P. Patrizia; Verona, Guglielmo; Marcoux, Julien; Giorgetti, Sofia; Taylor, Graham W.; Ellmerich, Stephan; Ballico, Maurizio; Zanini, Stefano; Pardon, Els; Al-Shawi, Raya; Simons, J. Paul; Corazza, Alessandra; Fogolari, Federico; Leri, Manuela; Stefani, Massimo; Bucciantini, Monica; Gillmore, Julian D.; Hawkins, Philip N.; Valli, Maurizia; Stoppini, Monica; Robinson, Carol V.; Steyaert, Jan; Esposito, Gennaro; Bellotti, Vittorio.

In: Scientific Reports, Vol. 7, 46711, 01.01.2017.

Research output: Contribution to journalArticle

Raimondi, S, Porcari, R, Mangione, PP, Verona, G, Marcoux, J, Giorgetti, S, Taylor, GW, Ellmerich, S, Ballico, M, Zanini, S, Pardon, E, Al-Shawi, R, Simons, JP, Corazza, A, Fogolari, F, Leri, M, Stefani, M, Bucciantini, M, Gillmore, JD, Hawkins, PN, Valli, M, Stoppini, M, Robinson, CV, Steyaert, J, Esposito, G & Bellotti, V 2017, 'A specific nanobody prevents amyloidogenesis of D76N β2- microglobulin in vitro and modifies its tissue distribution in vivo', Scientific Reports, vol. 7, 46711. https://doi.org/10.1038/srep46711
Raimondi, Sara ; Porcari, Riccardo ; Mangione, P. Patrizia ; Verona, Guglielmo ; Marcoux, Julien ; Giorgetti, Sofia ; Taylor, Graham W. ; Ellmerich, Stephan ; Ballico, Maurizio ; Zanini, Stefano ; Pardon, Els ; Al-Shawi, Raya ; Simons, J. Paul ; Corazza, Alessandra ; Fogolari, Federico ; Leri, Manuela ; Stefani, Massimo ; Bucciantini, Monica ; Gillmore, Julian D. ; Hawkins, Philip N. ; Valli, Maurizia ; Stoppini, Monica ; Robinson, Carol V. ; Steyaert, Jan ; Esposito, Gennaro ; Bellotti, Vittorio. / A specific nanobody prevents amyloidogenesis of D76N β2- microglobulin in vitro and modifies its tissue distribution in vivo. In: Scientific Reports. 2017 ; Vol. 7.
@article{bbde3996d2714184bf3c33b0248c187c,
title = "A specific nanobody prevents amyloidogenesis of D76N β2- microglobulin in vitro and modifies its tissue distribution in vivo",
abstract = "Systemic amyloidosis is caused by misfolding and aggregation of globular proteins in vivo for which effective treatments are urgently needed. Inhibition of protein self-aggregation represents an attractive therapeutic strategy. Studies on the amyloidogenic variant of β2-microglobulin, D76N, causing hereditary systemic amyloidosis, have become particularly relevant since fibrils are formed in vitro in physiologically relevant conditions. Here we compare the potency of two previously described inhibitors of wild type β2-microglobulin fibrillogenesis, doxycycline and single domain antibodies (nanobodies). The β2-microglobulin -binding nanobody, Nb24, more potently inhibits D76N β2-microglobulin fibrillogenesis than doxycycline with complete abrogation of fibril formation. In β2-microglobulin knock out mice, the D76N β2-microglobulin/Nb24 pre-formed complex, is cleared from the circulation at the same rate as the uncomplexed protein; however, the analysis of tissue distribution reveals that the interaction with the antibody reduces the concentration of the variant protein in the heart but does not modify the tissue distribution of wild type β2-microglobulin. These findings strongly support the potential therapeutic use of this antibody in the treatment of systemic amyloidosis.",
author = "Sara Raimondi and Riccardo Porcari and Mangione, {P. Patrizia} and Guglielmo Verona and Julien Marcoux and Sofia Giorgetti and Taylor, {Graham W.} and Stephan Ellmerich and Maurizio Ballico and Stefano Zanini and Els Pardon and Raya Al-Shawi and Simons, {J. Paul} and Alessandra Corazza and Federico Fogolari and Manuela Leri and Massimo Stefani and Monica Bucciantini and Gillmore, {Julian D.} and Hawkins, {Philip N.} and Maurizia Valli and Monica Stoppini and Robinson, {Carol V.} and Jan Steyaert and Gennaro Esposito and Vittorio Bellotti",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/srep46711",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A specific nanobody prevents amyloidogenesis of D76N β2- microglobulin in vitro and modifies its tissue distribution in vivo

AU - Raimondi, Sara

AU - Porcari, Riccardo

AU - Mangione, P. Patrizia

AU - Verona, Guglielmo

AU - Marcoux, Julien

AU - Giorgetti, Sofia

AU - Taylor, Graham W.

AU - Ellmerich, Stephan

AU - Ballico, Maurizio

AU - Zanini, Stefano

AU - Pardon, Els

AU - Al-Shawi, Raya

AU - Simons, J. Paul

AU - Corazza, Alessandra

AU - Fogolari, Federico

AU - Leri, Manuela

AU - Stefani, Massimo

AU - Bucciantini, Monica

AU - Gillmore, Julian D.

AU - Hawkins, Philip N.

AU - Valli, Maurizia

AU - Stoppini, Monica

AU - Robinson, Carol V.

AU - Steyaert, Jan

AU - Esposito, Gennaro

AU - Bellotti, Vittorio

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Systemic amyloidosis is caused by misfolding and aggregation of globular proteins in vivo for which effective treatments are urgently needed. Inhibition of protein self-aggregation represents an attractive therapeutic strategy. Studies on the amyloidogenic variant of β2-microglobulin, D76N, causing hereditary systemic amyloidosis, have become particularly relevant since fibrils are formed in vitro in physiologically relevant conditions. Here we compare the potency of two previously described inhibitors of wild type β2-microglobulin fibrillogenesis, doxycycline and single domain antibodies (nanobodies). The β2-microglobulin -binding nanobody, Nb24, more potently inhibits D76N β2-microglobulin fibrillogenesis than doxycycline with complete abrogation of fibril formation. In β2-microglobulin knock out mice, the D76N β2-microglobulin/Nb24 pre-formed complex, is cleared from the circulation at the same rate as the uncomplexed protein; however, the analysis of tissue distribution reveals that the interaction with the antibody reduces the concentration of the variant protein in the heart but does not modify the tissue distribution of wild type β2-microglobulin. These findings strongly support the potential therapeutic use of this antibody in the treatment of systemic amyloidosis.

AB - Systemic amyloidosis is caused by misfolding and aggregation of globular proteins in vivo for which effective treatments are urgently needed. Inhibition of protein self-aggregation represents an attractive therapeutic strategy. Studies on the amyloidogenic variant of β2-microglobulin, D76N, causing hereditary systemic amyloidosis, have become particularly relevant since fibrils are formed in vitro in physiologically relevant conditions. Here we compare the potency of two previously described inhibitors of wild type β2-microglobulin fibrillogenesis, doxycycline and single domain antibodies (nanobodies). The β2-microglobulin -binding nanobody, Nb24, more potently inhibits D76N β2-microglobulin fibrillogenesis than doxycycline with complete abrogation of fibril formation. In β2-microglobulin knock out mice, the D76N β2-microglobulin/Nb24 pre-formed complex, is cleared from the circulation at the same rate as the uncomplexed protein; however, the analysis of tissue distribution reveals that the interaction with the antibody reduces the concentration of the variant protein in the heart but does not modify the tissue distribution of wild type β2-microglobulin. These findings strongly support the potential therapeutic use of this antibody in the treatment of systemic amyloidosis.

UR - http://www.scopus.com/inward/record.url?scp=85035068065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035068065&partnerID=8YFLogxK

U2 - 10.1038/srep46711

DO - 10.1038/srep46711

M3 - Article

C2 - 28429761

AN - SCOPUS:85035068065

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 46711

ER -